A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

NCT05043922 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Recurrent Cancer

Interventions

DRUG: CYH33

Sponsor

Haihe Biopharma Co., Ltd.